B
Beyond Air, Inc. (XAIR)
NCM – Real vaqt narxi. Valyuta: USD
0.72
+0.03 (4.68%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.72
-0.00 (-0.32%)
Bozordan keyin: Mar 27, 2026, 7:43 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
0.72
+0.03 (4.68%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.72
-0.00 (-0.32%)
Bozordan keyin: Mar 27, 2026, 7:43 PM EDT
Beyond Air, Inc., tijorat bosqichidagi tibbiy va biofarmatsevtika kompaniyasi, nitrat oksidi (NO) generatori va yetkazib berish tizimi bo'lgan Lungfit platformasini ishlab chiqadi. U uchta segment orqali faoliyat yuritadi: Beyond Air, Beyond Cancer va NeuroNos. Kompaniya yangi tug'ilgan chaqaloqlarda o'tkir o'pka gipertenziyasini davolash uchun Lungfit PHni taklif etadi. U, shuningdek, kasalxona bemorlarida COVID-19 va bronxit kabi virusli o'pka infektsiyalarini, shu jumladan jamoatda orttirilgan pnevmoniyani davolash uchun LungFit PRO; va uyda tuberkulyozga bog'liq bo'lmagan mikobakteriyalar (NTM)ni davolash uchun LungFit GOni ishlab chiqmoqda. Bundan tashqari, kompaniya ko'plab qattiq va terini o'smalarini davolash uchun 1-faza klinik sinovlarida bo'lgan ultra-yuqori konsentratsiyali (UNO) va nevrologik kasalliklar va avtizm spektrining buzilishlarini davolash uchun selektiv neyronal nitrat oksidi sintaza (nNOS) inhibitörünü ishlab chiqmoqda. U Yissum Research Development Company of the Hebrew University of Jerusalem, LTD bilan avtizm spektrining buzilishi va boshqa nevrologik kasalliklarni davolash uchun neyronal nitrat oksidi sintaza inhibitörlerinin tijorat huquqlarini olish bo'yicha hamkorlikka ega. Kompaniya ilgari AIT Therapeutics, Inc. nomi bilan tanilgan va 2019-yil iyun oyida Beyond Air, Inc. nomini o'zgartirgan. Beyond Air, Inc. 2011-yilda tashkil etilgan va Nyu-Yorkning Garden City shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board |
| Dr. John Jett Ph.D. | Head of Research & Clinical Development |
| Mr. Adam T. Newman | Corporate Secretary |
| Mr. Amir Avniel | Chief Executive Officer of NeuroNOS |
| Mr. Daniel J. Moorhead CPA | Chief Financial Officer |
| Mr. Denton Drewell | Principal Accounting Officer & Controller |
| Mr. Michael A. Gaul | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-02-02 | 8-K | form8-k.htm |
| 2026-01-30 | S-3 | forms-3.htm |
| 2026-01-20 | 8-K | form8-k.htm |
| 2026-01-15 | 8-K | form8-k.htm |
| 2025-12-30 | 8-K | form8-k.htm |
| 2025-12-19 | DEF 14A | formdef14a.htm |
| 2025-12-11 | 8-K | form8-k.htm |
| 2025-11-28 | 8-K | form8-k.htm |
| 2025-11-21 | S-1 | forms-1.htm |
| 2025-11-14 | 8-K | form8-k.htm |
| Mr. Robert Scott Goodman |
| Interim Chief Commercial Officer & Director |
| Mr. Steven Adam Lisi | CEO & Director |